Innate PharmaIPHA
Market Cap: $182M
About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Employees: 179
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.07% less ownership
Funds ownership: 0.37% [Q1] → 0.3% (-0.07%) [Q2]
11% less funds holding
Funds holding: 9 [Q1] → 8 (-1) [Q2]
45% less capital invested
Capital invested by funds: $858K [Q1] → $469K (-$389K) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 39 / 128 met price target | 411%upside $11.50 | Buy Reiterated | 13 Sept 2024 |
Financial journalist opinion
Based on 5 articles about IPHA published over the past 30 days